A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 6, 2016, Pages 620-627

  Carr, A S ^a   Pelayo Negro, A L ^a,b   Evans, M R B ^a   Laura M ^a   Blake, J ^a,c   Stancanelli, C ^a   Iodice, V ^a   Wechalekar, A D ^d   Whelan, C J ^d   Gillmore, J D ^d   Hawkins, P N ^d   Reilly, M M ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARPAL TUNNEL SYNDROME; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; MISSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; SENSORIMOTOR NEUROPATHY; UNITED KINGDOM; AMYLOID NEUROPATHIES, FAMILIAL; COHORT ANALYSIS; DNA MUTATIONAL ANALYSIS; DOMINANT GENE; GENETICS; MIDDLE AGED; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSIOLOGY; RETROSPECTIVE STUDY;

ADENINE; PREALBUMIN; TYROSINE;

ADENINE; ADULT; AGED; AMYLOID NEUROPATHIES, FAMILIAL; COHORT STUDIES; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, DOMINANT; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEURAL CONDUCTION; NEUROLOGIC EXAMINATION; PERIPHERAL NERVOUS SYSTEM DISEASES; PHENOTYPE; PREALBUMIN; RETROSPECTIVE STUDIES; TYROSINE;

EID: 84940212299     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2015-310907     Document Type: Article

References (36)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909.
2. Quintas A, Vaz DC, Cardoso I, et al. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 2001;276:27207-13.
3. Ericzon BG, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Liver Transpl 2015;21:282-92.
4. Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000;123:1485-504.
5. Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology 2010;75:324-7.
6. Coelho T, Maia LF, Martins da Silva A, et al. Long-term effects of tafamidis for the treatment of transthyretin familial polyneuropathy. J Neurol 2013;260:2802-14.
7. Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013;310:2658-67.
8. Adams D, Thesudin M, Cauquil C, et al. FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep 2014;14:435.
9. Andrade C. A peculiar form of peripheral neuropathy. Brain 1952;75:408-27.
10. Coutinho P, Martins da Silva A, Kopes Lima J, et al. Forty years experience with type 1 amyloid neuropathy. In: Glenner GG, Pinho e Costa P, de Freitas AF, eds. Amyloid and amyloidosis. Amsterdam; Oxford; Princeton: Excerpta Medica, 1980:P88-98.
11. Sousa A, Andersson R, Drugge U, et al. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum Hered 1993;43:288-94.
12. Sousa A, Coelho T, Barros J, et al. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type 1 in Povoa do Varzim and Vila do Condo (North Portugal). Am J Med Genet 1995;60:512-21.
13. Kato-Motozaki Y, Ono K, Shima K, et al. Epidemiology of familial amyloid polyneuropathy in Japan: identification of a novel endemic focus. J Neurol Sci 2008;270:133-40.
14. Connors LH, Lim A, Prokaeva T, et al. Tabulation of human tranthyretin (TTR) variants, 2003. Amyloid 2003;10:160-84.
15. http://amyloidosismutations.com/mut-attr.php. May 2015.
16. Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcomes of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 2012;33:1120-7.
17. Wallace MR, Dwulet FE, Conneally PM, et al. Biocheminal and molecular genetic characterisation of a new variant prealbumin associated with hereditary amyloidosis. J Clin Invest 1986;78:6-12.
18. Staunton H, Dervan P, Kale R, et al. Hereditary amyloid polyneuropathy in north west Ireland. Brain 1987;110:1231-45.
19. Reilly MM, Staunton H, Harding AE. Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study. J Neurol Neurosurg Psychiatry 1995b;59:45-9.
20. Kotani N, Hattori T, Yamagata S, et al. Transthyretin Thr60Ala Appalachian-type mutation in a Japanese family with familial amyloidotic polyneuropathy. Amyloid 2002;9:31-4.
21. Reilly MM, Adams D, Booth DR, et al. Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy. Brain 1995;118(Pt 4):849-56.
22. Dohrn MF, Rocken C, De Bleecker JL, et al. Diagnostic Hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol 2013;260:3090-108.
23. Yang NCC, Lee MJ, Chao CC, et al. Clinical presentations and skin denervation in amyloid neuropathy due to transthyretin Ala97Ser. Neurology 2010;75:532-8.
24. Gonzalez-Duarte A, Lem-Carrillo M, Cardenas-Soto A. Description of tranthyretin S50A, S52P and G47A mutation in familial amyloidosis polyneuropathy. Amyloid 2013;20:221-5.
25. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Synposium on Amyloid and Amyloidosis. Am J Hematol 2005;79:319-28.
26. Hovaguimian A, Gibbons CH. Diagnosis and Treatment of Pain in small fibre neuropathy. Curr Pain Headache Rep 2011;15:193-200.
27. No authors listed]. Practice parameter for carpal tunnel syndrome (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1993;43:2406-9.
28. Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2011;16:191-8.
29. Lozeron P, Théaudin M, Mincheva Z, et al., French Network for FAP (CORNAMYL). Effect on disability and safety of tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol 2013;20:1539-45.
30. Burgess R. ed. New principles of best practice in clinical audit. 2nd edn. Radcliffe Publishing, 2011.
31. Tennent GA, Cafferty KD, Pepys MB, et al. Congo red overlay aids classification of amyloid deposits. In: Kule RC, Gertz MA, eds. Amyloid and amyloidosis. 1998. Pearl River, New York: Parthenon Publisheding, 1999:P160-162.
32. Thr-Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. Circulation 1995;91:962-7.
33. Carr AS, Pelayo-Negro AL, Jaunmuktane Z, et al. Yransthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy. Neuromuscul Disord 2015;25:511-15.
34. Arruda-Olsen AM, Zeldenrust SR, Dispenzieri A, et al. Genotype, echocardiography, and survival in familial transthyretin amyloidosis. Amyloid 2013;20:263-8.
35. Pinney JH, Smith CJ, Taube JB, et al. Systemic amyloidosis in England: an epidemiological study. Brit J Haem 2013;161:525-32.
36. Koike H, Hashimoto R, Tomita M, et al. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid 2011;18:53-62.